Search Results - "Kraychok, Iryna"

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia by Ghia, Paolo, Pluta, Andrzej, Wach, Malgorzata, Lysak, Daniel, Kozak, Tomas, Simkovic, Martin, Kaplan, Polina, Kraychok, Iryna, Illes, Arpad, de la Serna, Javier, Dolan, Sean, Campbell, Phillip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric, Lee, Jae Hoon, Liang, Wei, Patel, Priti, Quah, Cheng, Jurczak, Wojciech

“…Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study…”
Get full text

Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results by Ghia, Paolo, Pluta, Andrzej, Wach, Malgorzata, Lysak, Daniel, Kozak, Tomas, Simkovic, Martin, Kaplan, Polina, Kraychok, Iryna, Illes, Arpad, De La Serna, Javier, Dolan, Sean, Campbell, Philip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric Joseph, Lee, Jae Hoon, Wang, Denise, Patel, Priti, Quah, Cheng Seok, Jurczak, Wojciech

“…Abstract only 8015 Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients (pts) with CLL…”
Get full text

CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results by Ghia, Paolo, Pluta, Andrzej, Wach, Malgorzata, Lysak, Daniel, Kozak, Tomas, Simkovic, Martin, Kaplan, Polina, Kraychok, Iryna, Illes, Arpad, Serna, Javier de la, Dolan, Sean, Campbell, Philip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric J., Lee, Jae Hoon, Wang, Denise, Patel, Priti, Jurczak, Wojciech

“…Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL. The efficacy and safety of…”
Get full text

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study by Ghia, Paolo, Pluta, Andrzej, Wach, Malgorzata, Lysak, Daniel, Kozak, Tomas, Simkovic, Martin, Kaplan, Polina, Kraychok, Iryna, Illes, Arpad, De La Serna, Javier, Dolan, Sean, Campbell, Phillip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric J., Lee, Jae Hoon, Liang, Wei, Patel, Priti, Quah, Cheng, Jurczak, Wojciech

Get full text